Why Some Progressive European Countries Restrict Gender Affirming Care for Minors

It is often argued that the most progressive European countries have banned gender affirming care for minors because they want to deflect attention from their failures. However, this is not entirely accurate. In fact, many European countries still allow gender affirming care, with costs typically covered by their healthcare systems. Nevertheless, some countries are indeed revising their policies to introduce more stringent screening and protocols.

Gender Affirming Care in Europe

Gender affirming care, which includes psychological therapy, hormonal treatments, and surgical interventions, is legal and covered by healthcare in most European countries. For example, in the UK, the NHS provides gender-affirming care to those under 18, including puberty blockers. Similarly, in Sweden, gender affirming treatment for minors is available and covered by the national healthcare system.

France, Germany, and Italy also have policies that allow gender affirming care for minors, albeit with varying degrees of support and resources. These countries strive to provide the best possible care while ensuring the safety and well-being of their youth.

Changes in Policies and Protocols

It is crucial to understand that the changes in some European countries are not a complete ban on gender affirming care. Instead, they involve fine-tuning screening and protocols based on the assessment of patient need and best practices. This includes a greater caution in prescribing puberty blockers.

According to a recent study, children who received hormonal treatments had a significantly higher suicide rate of 19% when compared to those who only received therapy. Furthermore, these treatments were found to increase cranial pressure and decrease bone density in minors. Due to these risks, gender-affirming drugs have been reclassified as 'experimental' in most European countries, and their use on minors has been restricted.

Controversies and Debates

The decision to limit access to gender affirming care is not without controversy. Some argue that such restrictions are harmful and unjust, while others believe that they help ensure the safety of young people. The debate is complex and requires a balanced approach that considers both the benefits of support and protection.

It is important to note that the accusations of deflection or misrepresentation should be scrutinized. Right-wing propaganda often oversimplifies complex medical and social issues. It is essential to rely on credible sources and evidence-based research when evaluating these matters.

Conclusion

The situation regarding gender affirming care in Europe is nuanced and evolving. While some countries still support access to these treatments for minors, others are taking steps to ensure that care is administered with the highest standards of safety and efficacy. The ongoing research and discussions aim to find the best balance between supporting young people and safeguarding their health and well-being.

By staying informed and engaging in open, evidence-based discussions, we can contribute to a more understanding and supportive environment for all individuals, regardless of their gender identity.